Abiraterone (Abiraterone Acetate)

Generic Name

Abiraterone Acetate

Brand Names

Abiraterone, Zytiga, Akeega, YONSA, Abirtega

FDA approval date: April 28, 2011

Classification: Cytochrome P450 17A1 Inhibitor

Form: Tablet

What is Abiraterone (Abiraterone Acetate)?

Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer Metastatic high-risk castration-sensitive prostate cancer Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer . metastatic high-risk castration-sensitive prostate cancer .

Approved To Treat

Prostate Cancer

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Drug

Study Phase: Phase 3

Summary: Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after ...

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Partici...

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)

Who is this study for: Patients with Prostate Cancer

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Drug, Procedure, Radiation, Other

Study Drugs: Goserelin, Histrelin, Leuprolide & Triptorelin, Androgen Deprivation Therapy + Nilutamide, Flutamide, & Bicalutamide, Degarelix, Androgen Deprivation Therapy + Docetaxel +/- Prednisone, Androgen Deprivation Therapy + Abiraterone + Prednisone, Androgen Deprivation Therapy + Abiraterone + Methylprednisolone, Androgen Deprivation Therapy + Apalutamide, Androgen Deprivation Therapy + Enzalutamide

Study Phase: Phase 2/Phase 3

Summary: This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinica...

View All Clinical Trials